11 Aug 2021
Invitation to presentation of Xbrane Biopharma’s interim report January – June, 2021 on August 13, 2021.
30 Jun 2021
Xbrane Biopharma has carried out a directed share issue raising gross proceeds of SEK 380 millions
27 Jun 2021
Xlucane™ meets the primary endpoint in the pivotal Phase III trial with Xlucane™ – regulatory submission in EU and US planned for second half of 2021
16 May 2021
Xbrane announces ambition to generate positive operating cash flow monthly by late 2023/early 2024 and to initiate one new biosimilar development program per annum.
04 May 2021
Invitation to presentation of Xbrane Biopharma’s interim report January – March, 2021 on May 6, 2021.
15 Apr 2021
Xbrane Biopharma expands in-house Biosimilar development capabilities with new Biotech lab and invites participants to Virtual Capital Markets day on May 17.